DRP Journal

Discover Research Profit

Finance 

Psycheceutical Bioscience Inc (OTCMKTS:BWVI) Stock In Focus After Recent News

Ian Leigh

The bioscience company Psycheceutical Bioscience Inc (OTCMKTS:BWVI) is one of the companies which may well be tracked this morning by investors in light of the developments from yesterday. The company, which is involved in the development of advanced mental health treatments, announced yesterday that it had sent in a filing for a provisional patent to the United States Patent and Trademark Office.

Psycheceutical Bioscience Provisional Patent Application for Novel Ketamine Topical for the Treatment of PTSD

The patent is for the very first ketamine topical that is meant for the treatment of those suffering from post-traumatic stress disorder. The news about a new patent application can often come as a source of optimism among investors and it remains to be seen if the Psycheceutical Bioscience makes an upward move or not.

The company has come up with a delivery system that has been designed in such a way as to send in the neuro-active compounds to the back of the patient’s neck. That way the product would take effect immediately and provide comfort to the patient. The formulation that the company has come up with is meant to reduce the side effects of ketamine as much as possible. It could be a good idea to add the stock to your watch list.

Ian Leigh

Ian Leigh is a specialist in analyzing stocks, SEC and OTC filings, and financials of public and privately-held companies. He has played a significant role in M&A activity, consulting with publicly-held firms on acquisitions and divestitures. He also consults on valuations and branding. He lectures at major universities and teaches at specialty financial schools.